Drug: Tykerb (lapatinib)
Indication: Metastatic breast cancer
Approval Date: March 13, 2007
Scoop: The FDA gave its approval to Tykerb for metastatic breast cancer in combination with Xeloda. Tykerb is also in trials for metastatic brain cancer. Tykerb has an advantage over the blockbuster Herceptin because it is administered in pill form while Herceptin is injected. And data supports that Tykerb in combination with Xeloda is more effective that a treatment consisting only of Xeloda.
FDA approves Tykerb for breast cancer. Report